## Rafael Marcos-Gragera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2310215/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37â€^513â€^025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, The, 2018, 391, 1023-1075.	6.3	3,228
2	Global surveillance of cancer survival 1995–2009: analysis of individual data for 25â€^676â€^887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, The, 2015, 385, 977-1010.	6.3	1,863
3	Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncology, The, 2014, 15, 23-34.	5.1	1,554
4	International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncology, The, 2017, 18, 719-731.	5.1	992
5	Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. Lancet Oncology, The, 2014, 15, 35-47.	5.1	799
6	Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood, 2010, 116, 3724-3734.	0.6	784
7	Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. European Journal of Cancer, 2015, 51, 2130-2143.	1.3	344
8	Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. Lancet Oncology, The, 2017, 18, 1022-1039.	5.1	285
9	Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncology, The, 2014, 15, 931-942.	5.1	229
10	Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2191-2205.	1.3	205
11	Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncology, The, 2021, 22, 1002-1013.	5.1	203
12	InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood, 2010, 116, e90-e98.	0.6	200
13	Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. Cancer Epidemiology, 2014, 38, 670-678.	0.8	174
14	Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1170-1178.	1.3	174
15	Cancer incidence in Spain, 2015. Clinical and Translational Oncology, 2017, 19, 799-825.	1.2	169
16	Incidence, survival and prevalence of myeloid malignancies in Europe. European Journal of Cancer, 2012, 48, 3257-3266.	1.3	158
17	Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design. Gaceta Sanitaria, 2015, 29, 308-315.	0.6	158
18	Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89â€~828 children from 198 registries in 53 countries. Lancet Haematology,the, 2017, 4, e202-e217.	2.2	141

#	Article	IF	CITATIONS
19	Survival for oesophageal, stomach and small intestine cancers in Europe 1999–2007: Results from EUROCARE-5. European Journal of Cancer, 2015, 51, 2144-2157.	1.3	138
20	Incidencia y mortalidad del cÃ <sub>i</sub> ncer cutÃ <sub>i</sub> neo en España: revisión sistemática y metaanálisis. Actas Dermo-sifiliográficas, 2016, 107, 318-328.	0.2	135
21	Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: Results of EUROCARE-5. European Journal of Cancer, 2015, 51, 2169-2178.	1.3	115
22	Cost-Effectiveness and Harm-Benefit Analyses of Risk-Based Screening Strategies for Breast Cancer. PLoS ONE, 2014, 9, e86858.	1.1	113
23	Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes and Control, 2019, 30, 489-499.	0.8	101
24	The EUROCARE-5 study on cancer survival in Europe 1999–2007: Database, quality checks and statistical analysis methods. European Journal of Cancer, 2015, 51, 2104-2119.	1.3	97
25	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	2.0	96
26	On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2158-2168.	1.3	93
27	Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. European Journal of Cancer, 2013, 49, 2565-2578.	1.3	91
28	Recent Changes in Breast Cancer Incidence in Spain, 1980–2004. Journal of the National Cancer Institute, 2009, 101, 1584-1591.	3.0	90
29	Long-term survival expectations of cancer patients in Europe in 2000–2002. European Journal of Cancer, 2009, 45, 1028-1041.	1.3	87
30	Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Information System): a population-based study. Lancet Oncology, The, 2018, 19, 1159-1169.	5.1	85
31	Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: Results from the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2206-2216.	1.3	82
32	Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2179-2190.	1.3	80
33	Breast cancer risk and night shift work in a case–control study in a Spanish population. European Journal of Epidemiology, 2016, 31, 867-878.	2.5	76
34	Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5. European Journal of Cancer, 2015, 51, 2217-2230.	1.3	75
35	Survival patterns in lung and pleural cancer in Europe 1999–2007: Results from the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2242-2253.	1.3	73
36	Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. European Journal of Cancer, 2017, 77, 140-152.	1.3	72

RAFAEL MARCOS-GRAGERA

#	Article	IF	CITATIONS
37	Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. European Journal of Cancer, 2012, 48, 1167-1175.	1.3	71
38	Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. European Journal of Cancer, 2007, 43, 144-148.	1.3	69
39	Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica, 2011, 96, 720-728.	1.7	68
40	Age and case mix-standardised survival for all cancer patients in Europe 1999–2007: Results of EUROCARE-5, a population-based study. European Journal of Cancer, 2015, 51, 2120-2129.	1.3	66
41	Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica, 2013, 98, 230-238.	1.7	65
42	Hodgkin disease survival in Europe and the U.S Cancer, 2006, 107, 352-360.	2.0	64
43	Survival of European patients with central nervous system tumors. International Journal of Cancer, 2012, 131, 173-185.	2.3	64
44	Geographical patterns of childhood cancer incidence in Europe, 1988–1997. Report from the Automated Childhood Cancer Information System project. European Journal of Cancer, 2006, 42, 1952-1960.	1.3	63
45	Childhood cancer incidence and survival in Spain. Annals of Oncology, 2010, 21, iii103-iii110.	0.6	62
46	Racial/ethnic and socioeconomic disparities in survival among children with acute lymphoblastic leukemia in California, 1988-2011: A population-based observational study. Pediatric Blood and Cancer, 2015, 62, 1819-1825.	0.8	61
47	Effect of mistimed eating patterns on breast and prostate cancer risk (MCCâ€ <del>S</del> pain <i>Study</i> ). International Journal of Cancer, 2018, 143, 2380-2389.	2.3	61
48	Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecologic Oncology, 2013, 130, 609-614.	0.6	60
49	Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Research, 2014, 16, R3.	2.2	60
50	High cancer mortality for US-born Latinos: evidence from California and Texas. BMC Cancer, 2017, 17, 478.	1.1	60
51	Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2231-2241.	1.3	56
52	Cancer survival in adult patients in Spain. Results from nine population-based cancer registries. Clinical and Translational Oncology, 2018, 20, 201-211.	1.2	56
53	Cancer survival in Spain: estimate for nine major cancers. Annals of Oncology, 2010, 21, iii21-iii29.	0.6	55
54	Cancer incidence in AIDS patients in Catalonia, Spain. European Journal of Cancer, 2007, 43, 1085-1091.	1.3	51

#	Article	IF	CITATIONS
55	Lung cancer prognosis in Spain: The role of histology, age and sex. Respiratory Medicine, 2012, 106, 1301-1308.	1.3	50
56	Adherence to nutritionâ€based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the <scp>MCC</scp> â€ <scp>S</scp> pain case–control study. International Journal of Cancer, 2017, 141, 83-93.	2.3	48
57	Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study. European Journal of Cancer, 2015, 51, 2254-2268.	1.3	47
58	Epidemiology of rare cancers and inequalities in oncologic outcomes. European Journal of Surgical Oncology, 2019, 45, 3-11.	0.5	47
59	Trends in incidence and survival analysis in non-melanoma skin cancer from 1994 to 2012 in Girona, Spain: A population-based study. Cancer Epidemiology, 2016, 45, 6-10.	0.8	40
60	Time trends of cancer incidence and mortality in Catalonia during 1993–2007. Clinical and Translational Oncology, 2014, 16, 18-28.	1.2	37
61	Dietary Inflammatory Index, Dietary Non-Enzymatic Antioxidant Capacity, and Colorectal and Breast Cancer Risk (MCC-Spain Study). Nutrients, 2019, 11, 1406.	1.7	37
62	Breast cancer incidence and overdiagnosis in Catalonia (Spain). Breast Cancer Research, 2010, 12, R58.	2.2	36
63	Cancer prevalence estimates in Europe at the beginning of 2000. Annals of Oncology, 2013, 24, 1660-1666.	0.6	36
64	Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. Haematologica, 2013, 98, 744-752.	1.7	35
65	Geographical variability in survival of European children with central nervous system tumours. European Journal of Cancer, 2017, 82, 137-148.	1.3	33
66	<p>Validation Of Cancer Diagnoses In Electronic Health Records: Results From The Information System For Research In Primary Care (SIDIAP) In Northeast Spain</p> . Clinical Epidemiology, 2019, Volume 11, 1015-1024.	1.5	33
67	Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. European Journal of Cancer, 2008, 44, 579-587.	1.3	32
68	Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic?. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1083-1088.	1.3	32
69	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Sporadic Burkitt Lymphoma/Leukemia: The Interlymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 106-114.	0.9	32
70	The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study. PLoS ONE, 2016, 11, e0159672.	1.1	32
71	Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. Breast Cancer Research and Treatment, 2019, 175, 733-740.	1.1	32
72	Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis. Actas Dermo-sifiliogrÃ <sub>i</sub> ficas, 2016, 107, 318-328.	0.2	31

#	Article	IF	CITATIONS
73	Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: AÂEUROCARE-5 study. European Journal of Cancer, 2017, 84, 335-353.	1.3	29
74	Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: Results from the Girona Cancer Registry (1994–2013). Cancer Epidemiology, 2017, 50, 1-8.	0.8	29
75	Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study. Environment International, 2019, 122, 389-399.	4.8	28
76	Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer. International Journal of Cancer, 2019, 144, 2118-2127.	2.3	27
77	Treatment challenges in and outside a network setting: Soft tissue sarcomas. European Journal of Surgical Oncology, 2019, 45, 31-39.	0.5	27
78	Treatment challenges in and outside a network setting: Head and neck cancers. European Journal of Surgical Oncology, 2019, 45, 40-45.	0.5	27
79	Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study. BMC Cancer, 2016, 16, 660.	1.1	26
80	Data Quality in Rare Cancers Registration: The Report of the RARECARE Data Quality Study. Tumori, 2017, 103, 22-32.	0.6	26
81	Serum 25-hydroxyvitamin D and breast cancer risk by pathological subtype (MCC-Spain). Journal of Steroid Biochemistry and Molecular Biology, 2018, 182, 4-13.	1.2	26
82	Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica, 2013, 98, e95-e97.	1.7	25
83	Impact of Risk Factors on Different Interval Cancer Subtypes in a Population-Based Breast Cancer Screening Programme. PLoS ONE, 2014, 9, e110207.	1.1	24
84	Hormonal contraception and postmenopausal hormone therapy in Spain. Menopause, 2015, 22, 1138-1146.	0.8	23
85	Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study. BMC Public Health, 2018, 18, 1134.	1.2	23
86	Multimorbidity and short-term overall mortality among colorectal cancer patients in Spain: A population-based cohort study. European Journal of Cancer, 2020, 129, 4-14.	1.3	23
87	Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005. Journal of Neuro-Oncology, 2011, 101, 117-123.	1.4	22
88	Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. European Journal of Surgical Oncology, 2019, 45, 67-74.	0.5	22
89	Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain. Annals of Oncology, 2010, 21, iii90-iii96.	0.6	21
90	Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study. Haematologica, 2018, 103, 1881-1888.	1.7	21

#	Article	IF	CITATIONS
91	The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3). Neuro-Oncology, 2021, 23, 1765-1776.	0.6	21
92	Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN). Cancers, 2022, 14, 2441.	1.7	21
93	Effectiveness of early detection on breast cancer mortality reduction in Catalonia (Spain). BMC Cancer, 2009, 9, 326.	1.1	20
94	Neuroendocrine tumors: A population-based study of incidence and survival in Girona province, 1994–2004. Cancer Epidemiology, 2011, 35, e49-e54.	0.8	20
95	Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study. World Journal of Surgical Oncology, 2015, 13, 47.	0.8	20
96	Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988–2011: a populationâ€based study. British Journal of Haematology, 2016, 173, 292-302.	1.2	20
97	Towards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and multiple diagnoses. European Journal of Cancer, 2015, 51, 1109-1122.	1.3	19
98	Night shift work and chronic lymphocytic leukemia in the MCCâ€Spain case–control study. International Journal of Cancer, 2016, 139, 1994-2000.	2.3	18
99	Is low survival for cancer in Eastern Europe due principally to late stage at diagnosis?. European Journal of Cancer, 2018, 93, 127-137.	1.3	18
100	Effect of time of day of recreational and household physical activity on prostate and breast cancer risk ( MCCâ€ <del>S</del> pain study). International Journal of Cancer, 2021, 148, 1360-1371.	2.3	18
101	Accurately estimating breast cancer survival in Spain: cross-matching local cancer registries with the National Death Index. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2009, 26, 51-54.	0.6	17
102	Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983–2007. Breast, 2012, 21, 646-651.	0.9	17
103	Risk of breast cancer and residential proximity to industrial installations: New findings from a multicase-control study (MCC-Spain). Environmental Pollution, 2018, 237, 559-568.	3.7	17
104	Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000–2014 in 59 countries (CONCORD-3). British Journal of Dermatology, 2022, 187, 364-380.	1.4	17
105	Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas. Statistics in Medicine, 2012, 31, 978-987.	0.8	16
106	<p>Multimorbidity by Patient and Tumor Factors and Time-to-Surgery Among Colorectal Cancer Patients in Spain: A Population-Based Study</p> . Clinical Epidemiology, 2020, Volume 12, 31-40.	1.5	16
107	Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clinical and Translational Oncology, 2021, 23, 1429-1439.	1.2	16
108	Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. European Journal of Surgical Oncology, 2019, 45, 75-80.	0.5	15

#	Article	IF	CITATIONS
109	Population-based incidence of childhood leukaemias and lymphomas in Spain (1993–2002). European Journal of Cancer Prevention, 2010, 19, 247-255.	0.6	14
110	The moderate decrease in invasive cervical cancer incidence rates in Spain (1980–2004): limited success of opportunistic screening?. Annals of Oncology, 2010, 21, iii61-iii68.	0.6	14
111	Trends in prostate cancer survival in Spain: results from population-based cancer registries. Clinical and Translational Oncology, 2012, 14, 458-464.	1.2	14
112	Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study. Breast Cancer Research and Treatment, 2020, 181, 667-678.	1.1	14
113	Estimation of age- and stage-specific Catalan breast cancer survival functions using US and Catalan survival data. BMC Cancer, 2009, 9, 98.	1.1	13
114	Urinary Incontinence and Prostate Cancer: A Progressive Rehabilitation Program Design. Rehabilitation Nursing, 2014, 39, 271-280.	0.3	13
115	Perinatal and childhood factors and risk of breast cancer subtypes in adulthood. Cancer Epidemiology, 2016, 40, 22-30.	0.8	13
116	Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S77-S84.	0.6	13
117	Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain). Scientific Reports, 2021, 11, 23274.	1.6	13
118	Rápido incremento de la incidencia del melanoma in situ en Girona (España) 1994–2005. ¿Efectividad de la campañas de diagnóstico precoz?. Actas Dermo-sifiliográficas, 2010, 101, 561-563.	0.2	12
119	Incidence variation of prostate and cervical cancer according to socioeconomic level in the Girona Health Region. BMC Public Health, 2014, 14, 1079.	1.2	12
120	Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly. Clinical and Translational Oncology, 2018, 20, 647-657.	1.2	12
121	Compositional analysis of dietary patterns. Statistical Methods in Medical Research, 2019, 28, 2834-2847.	0.7	12
122	Adherence to the 2018 WCRF/AICR cancer prevention guidelines and chronic lymphocytic leukemia in the MCC-Spain study. Cancer Epidemiology, 2020, 64, 101629.	0.8	12
123	Missing data imputation and synthetic data simulation through modeling graphical probabilistic dependencies between variables (ModGraProDep): An application to breast cancer survival. Artificial Intelligence in Medicine, 2020, 107, 101875.	3.8	12
124	Lung, Breast and Colorectal Cancer Incidence by Socioeconomic Status in Spain: A Population-Based Multilevel Study. Cancers, 2021, 13, 2820.	1.7	12
125	Effects of deprivation on the geographical variability of larynx cancer incidence in men, Girona (Spain) 1994–2004. Cancer Epidemiology, 2010, 34, 109-115.	0.8	11
126	Spatial Variability in Relative Survival from Female Breast Cancer. Journal of the Royal Statistical Society Series A: Statistics in Society, 2012, 175, 107-134.	0.6	11

#	Article	IF	CITATIONS
127	Temporal trends of incidence and survival of sarcoma of digestive tract including Gastrointestinal Stromal Tumours (GIST) in two areas of the north-east of Spain in the period 1981–2005: a population-based study. Clinical and Translational Oncology, 2014, 16, 660-667.	1.2	11
128	Fruit and vegetable intake and vitamin C transporter gene (SLC23A2) polymorphisms in chronic lymphocytic leukaemia. European Journal of Nutrition, 2017, 56, 1123-1133.	1.8	11
129	Incidence and survival time trends for Spanish children and adolescents with leukaemia from 1983 to 2007. Clinical and Translational Oncology, 2017, 19, 301-316.	1.2	11
130	Long-term crude probabilities of death among breast cancer patients by age and stage: a population-based survival study in Northeastern Spain (Girona–Tarragona 1985–2004). Clinical and Translational Oncology, 2018, 20, 1252-1260.	1.2	11
131	Bayesian estimates of the incidence of rare cancers in Europe. Cancer Epidemiology, 2018, 54, 95-100.	0.8	11
132	Evaluation of the interval cancer rate and its determinants on the Girona health region's early breast cancer detection program. BMC Cancer, 2014, 14, 558.	1.1	10
133	Consumption of Ultra-Processed Food and Drinks and Chronic Lymphocytic Leukemia in the MCC-Spain Study. International Journal of Environmental Research and Public Health, 2021, 18, 5457.	1.2	10
134	Survival trends for primary liver cancer, 1995–2009: analysis of individual data for 578,740 patients from 187 population-based registries in 36 countries (CONCORD-2). Annals of Cancer Epidemiology, 0, 3, 6-6.	1.8	10
135	Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): A population-based study, 1993–2007. Leukemia Research, 2012, 36, 1262-1266.	0.4	9
136	Cancer incidence and mortality projections up to 2020 in Catalonia by means of Bayesian models. Clinical and Translational Oncology, 2014, 16, 714-724.	1.2	9
137	Population-based survival analyses of central nervous system tumors from 1994 to 2008. An up-dated study in the temozolomide-era. Cancer Epidemiology, 2014, 38, 244-247.	0.8	9
138	ls survival in myeloid malignancies really improving? A retrospective 15-year population-based study. Leukemia and Lymphoma, 2015, 56, 896-902.	0.6	9
139	Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results. BMJ Open, 2019, 9, e031904.	0.8	9
140	Cause-specific mortality after a breast cancer diagnosis: a cohort study of 10,195 women in Girona and Tarragona. Clinical and Translational Oncology, 2019, 21, 1014-1025.	1.2	9
141	Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study. European Journal of Surgical Oncology, 2020, 46, 1151-1159.	0.5	9
142	Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening. European Radiology, 2022, 32, 621-629.	2.3	9
143	Epidemiology and Molecular Profile of Mucosal Melanoma: A Population-Based Study in Southern Europe. Cancers, 2022, 14, 780.	1.7	9
144	Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain. Cancer Epidemiology, 2019, 58, 8-11.	0.8	8

#	Article	IF	CITATIONS
145	Population-based survival of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain. Cancer Epidemiology, 2020, 69, 101841.	0.8	8
146	Occupational Heat Exposure and Breast Cancer Risk in the MCC-Spain Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 364-372.	1.1	8
147	Incidence Patterns and Trends of non-Central Nervous System Solid Tumours in Children and Adolescents. A Collaborative Study of the Spanish Population Based Cancer Registries. Journal of Cancer, 2016, 7, 335-343.	1.2	7
148	Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16Âyears of epidemiological data from the province of Girona, Spain. Cancer Causes and Control, 2018, 29, 379-382.	0.8	7
149	Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study. Cancer Epidemiology, 2018, 52, 106-111.	0.8	7
150	Disparities in the management of cutaneous malignant melanoma. A populationâ€based highâ€resolution study. European Journal of Cancer Care, 2019, 28, e13043.	0.7	7
151	Fatty acid intake and breast cancer in the Spanish multicase–control study on cancer (MCC-Spain). European Journal of Nutrition, 2020, 59, 1171-1179.	1.8	7
152	Adherence to Clinical Practice Guidelines and Colorectal Cancer Survival: A Retrospective High-Resolution Population-Based Study in Spain. International Journal of Environmental Research and Public Health, 2020, 17, 6697.	1.2	7
153	Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening. PLoS ONE, 2021, 16, e0248930.	1.1	7
154	The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study. BMC Cancer, 2021, 21, 1048.	1.1	7
155	Incidence and survival of Hodgkin lymphoma patients in Girona (Spain) over three decades: a population-based study. European Journal of Cancer Prevention, 2017, 26, S164-S169.	0.6	6
156	Childhood and adolescent lymphoma in Spain: incidence and survival trends over 20Âyears. Clinical and Translational Oncology, 2018, 20, 1289-1301.	1.2	6
157	Domain-specific patterns of physical activity and risk of breast cancer sub-types in the MCC-Spain study. Breast Cancer Research and Treatment, 2019, 177, 749-760.	1.1	6
158	Incidence of myeloid neoplasms in Spain (2002–2013): a population-based study of the Spanish network of cancer registries. Scientific Reports, 2022, 12, 323.	1.6	6
159	Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred. Scientific Reports, 2022, 12, 8097.	1.6	6
160	Estimating Long-Term Crude Probability of Death among Young Breast Cancer Patients: A Bayesian Approach. Tumori, 2016, 102, 555-561.	0.6	5
161	Validating a breast cancer score in Spanish women. The MCC-Spain study. Scientific Reports, 2018, 8, 3036.	1.6	5
162	Patterns of increased incidence and survival of cutaneous melanoma in Girona (Spain) 1994–2013: a population-based study. Clinical and Translational Oncology, 2018, 20, 1617-1625.	1.2	5

#	Article	IF	CITATIONS
163	Occupational Exposure to Pesticides and Chronic Lymphocytic Leukaemia in the MCC-Spain Study. International Journal of Environmental Research and Public Health, 2020, 17, 5174.	1.2	5
164	The Relation of CUN-BAE Index with Body Mass Index and Waist Circumference in Adults Aged 50 to 85 Years: The MCC-Spain Study. Nutrients, 2020, 12, 996.	1.7	5
165	Incidence and survival of central nervous system tumors in childhood and adolescence in Girona (Spain) 1990–2013: national and international comparisons. Clinical and Translational Oncology, 2019, 21, 1177-1185.	1.2	5
166	Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994–2013). Clinical and Translational Oncology, 2018, 20, 1628-1630.	1.2	4
167	Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. European Journal of Surgical Oncology, 2019, 45, 60-66.	0.5	4
168	Quality of Life in a Cohort of 1078 Women Diagnosed with Breast Cancer in Spain: 7-Year Follow-Up Results in the MCC-Spain Study. International Journal of Environmental Research and Public Health, 2020, 17, 8411.	1.2	4
169	Association between Polyphenol Intake and Breast Cancer Risk by Menopausal and Hormone Receptor Status. Nutrients, 2020, 12, 994.	1.7	4
170	Comorbidities at Diagnosis, Survival, and Cause of Death in Patients with Chronic Lymphocytic Leukemia: A Population-Based Study. International Journal of Environmental Research and Public Health, 2021, 18, 701.	1.2	4
171	Dietary Constituents: Relationship with Breast Cancer Prognostic (MCC-SPAIN Follow-Up). International Journal of Environmental Research and Public Health, 2021, 18, 84.	1.2	4
172	Prostate Cancer and Quality of Life: Analysis of Response Shift Using Triangulation Between Methods. Journal of Gerontological Nursing, 2014, 40, 32-41.	0.3	4
173	Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor. European Journal of Dermatology, 2021, 31, 616-622.	0.3	4
174	Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Age–Period–Cohort Modelling. International Journal of Environmental Research and Public Health, 2022, 19, 1404.	1.2	4
175	Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S121-S127.	0.6	3
176	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. European Journal of Surgical Oncology, 2019, 45, 46-51.	0.5	3
177	Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years. International Journal of Environmental Research and Public Health, 2020, 17, 9538.	1.2	3
178	Kaposi sarcoma incidence, survival and trends: Data from the information network on rare cancers in Europe (RARECAREnet). Cancer Epidemiology, 2021, 70, 101877.	0.8	3
179	Differences in the management and survival of metastatic colorectal cancer in Europe. A population-based study. Digestive and Liver Disease, 2021, 53, 639-645.	0.4	3
180	Gynaecological malignancies after breast cancer diagnosis: A population-based study. Clinical Journal of Obstetrics and Gynecology, 2019, 2, 113-118/.	0.1	3

#	Article	IF	CITATIONS
181	A common error in the ecological regression of cancer incidence on the deprivation index. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2013, 34, 83-91.	0.6	3
182	Differences in the Impact of COVID-19 on Pathology Laboratories and Cancer Diagnosis in Girona. International Journal of Environmental Research and Public Health, 2021, 18, 13269.	1.2	3
183	World-wide trends in net survival from pancreatic cancer by morphological sub-type: An analysis of 1,258,329 adults diagnosed in 58 countries during 2000–2014 (CONCORD-3). Cancer Epidemiology, 2022, 80, 102196.	0.8	3
184	¿EstÃ; aumentando el cÃ;ncer cutÃ;neo en nuestro paÃs?. Piel, 2012, 27, 295-299.	0.0	2
185	Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries. Breast, 2013, 22, 476-481.	0.9	2
186	Mortality of women with ductal carcinoma in situ of the breast: a population-based study from the Girona province, Spain (1994–2013). Clinical and Translational Oncology, 2019, 21, 891-899.	1.2	2
187	The Dietary Inflammatory Index and Chronic Lymphocytic Leukaemia in the MCC Spain Study. Nutrients, 2020, 12, 48.	1.7	2
188	A population perspective on the use of external beam radiotherapy in Catalonia, Spain. Clinical and Translational Oncology, 2020, 22, 2222-2229.	1.2	2
189	Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study. Breast Cancer Research and Treatment, 2020, 183, 439-450.	1.1	2
190	Predicting the rising incidence and mortality of endometrial cancers among women aged 65-74 years in Catalonia. Maturitas, 2021, 144, 11-15.	1.0	2
191	Population-based risk assessment of second primary cancers following a first head and neck cancer: patterns of association and difficulties of its analysis. Clinical and Translational Oncology, 2021, 23, 788-798.	1.2	2
192	Abstract P4-09-11: Fatty Acid Synthase (FASN) expression in Triple-Negative Breast Cancer. , 2012, , .		2
193	Differences in breast cancer-risk factors between screen-detected and non-screen-detected cases (MCC-Spain study). Cancer Causes and Control, 2021, , 1.	0.8	2
194	Estimaciones de la incidencia de las neoplasias hematológicas en España, 2021: estudio de la Red Española de Registros de Cáncer (REDECAN). Medicina ClÃnica, 2022, 158, 284-290.	0.3	2
195	Population-Based Analysis of Trends in Incidence and Survival of Human Papilloma Virus-Related Oropharyngeal Cancer in a Low-Burden Region of Southern Europe. International Journal of Environmental Research and Public Health, 2022, 19, 4802.	1.2	2
196	1LBA Is Europe doing better in cancer care since the 90s? The latestfindings from the EUROCARE-5 study. European Journal of Cancer, 2015, 51, S707.	1.3	1
197	Insulinâ€like growth factor levels and chronic lymphocytic leukaemia: results from the MCC â€Spain and EpiLymphâ€Spain studies. British Journal of Haematology, 2019, 185, 608-612.	1.2	1
198	Validation of self-reported perception of proximity to industrial facilities: MCC-Spain study. Environment International, 2020, 135, 105316.	4.8	1

#	Article	IF	CITATIONS
199	P-216 Incidence and trends of biliary tract cancer in Girona: A population-based study from the Girona Cancer Registry (1994-2016). Annals of Oncology, 2020, 31, S160-S161.	0.6	1
200	Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study. Scientific Reports, 2021, 11, 5375.	1.6	1
201	Social mobility and healthy behaviours from a gender perspective in the Spanish multicase-control study (MCC-Spain). PLoS ONE, 2021, 16, e0251447.	1.1	1
202	Predictors of Early Death and Survival Among Children, Adolescents and Young Adults with Acute Myeloid Leukemia in California, 1988-2011: A Population-Based Study. Blood, 2015, 126, 1323-1323.	0.6	1
203	Registration of Urothelial Tumours in Cancer Registries: How to Improve and Make It More Useful?. International Journal of Environmental Research and Public Health, 2022, 19, 2714.	1.2	1
204	No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach. International Journal of Environmental Research and Public Health, 2022, 19, 3605.	1.2	1
205	Bayesian variable selection and survival modeling: assessing the Most important comorbidities that impact lung and colorectal cancer survival in Spain. BMC Medical Research Methodology, 2022, 22, 95.	1.4	1
206	3â€Social inequities in the risk of death for women diagnosed with an invasive breast cancer in the girona province, spain. , 2018, , .		0
207	PV-0253 A critical quality appraisal of studies estimating the cost of radiotherapy. Radiotherapy and Oncology, 2019, 133, S123-S124.	0.3	0
208	P-243 Incidence and survival of pancreatic neuroendocrine tumours in Girona, Spain. Annals of Oncology, 2020, 31, S169.	0.6	0
209	Does the Morphology of Cutaneous Melanoma Help Explain the International Differences in Survival? Results from 1,583,484 Adults Diagnosed During 2000-2014 in 59 Countries (CONCORD-3). SSRN Electronic Journal, 0, , .	0.4	0
210	Occupational heat exposure and breast cancer risk (MCC-Spain study). ISEE Conference Abstracts, 2020, 2020, .	0.0	0
211	Estimates of the incidence of hematological neoplasms in Spain, 2021: Study of the Spanish Network of Cancer Registries (REDECAN). Medicina ClÃnica (English Edition), 2022, 158, 284-284.	0.1	0